Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 2, 2009, Pages 187-195

  Chen, Chih Ying ^a   Gerhard, Tobias ^b,c   Winterstein, Almut G ^a,d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; HYPNOTIC AGENT; LITHIUM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADJUSTMENT DISORDER; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CHILD; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; CONDUCT DISORDER; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG UTILIZATION; FEMALE; FOSTER CARE; HUMAN; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRESCHOOL CHILD; PSYCHIATRIST; RACE DIFFERENCE; RURAL AREA; SCHIZOPHRENIA; SCHOOL CHILD; TIC; URBAN AREA;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; DEMOGRAPHY; FAMILY PRACTICE; FEMALE; FOSTER HOME CARE; HUMANS; MALE; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PROPYLAMINES; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 65249184397     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.096     Document Type: Article

References (19)

1. Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, Riddle M, Oatis M, Greenhill L, Skrobala A, March J, Gammon P, Robinson J, Lazell R, McMahon DJ, Ritz L: Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 44:418-27, 2005.
2. American Psychiatric Association: Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR). Washington (DC): American Psychiatric Association, 2000.
3. Bole M, Lynch FL, and DeBar LL: Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. J Child Adolesc Psychopharmacol 11:43-52, 2001.
4. Centers for Disease Control and Prevention: Mental Health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003. MMWR Morb Mortal Wkly Rep 54:842-847, 2005.
5. Chan E, Hopkins MR, Perrin JM, Herrerias C, Homer CJ: Diagnostic practices for attention deficit hyperactivity disorder: A national survey of primary care physicians. Ambul Pediatr 5:201-8, 2005.
6. Cox ER, Motheral BR, Henderson RR, Mager D: Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: Results from a commercially insured US sample. Pediatrics 111:237-243, 2003.
7. Dopheide JA: ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention- deficit/hyperactivity disorder in pediatric patients. Am J Health Syst Pharm 62:1502-1509, 2005.
8. Kwasman AB, Tinsley J, Lepper HS: Pediatricians' knowledge and attitudes concerning diagnosis and treatment of attention deficit and hyperactivity disorders. A national survey approach. Arch Pediatr Adolesc Med 149:1211-1216, 1995.
9. McEvoy GK, American Society of Health-System Pharmacists. Essentials 2004-2005: AHFS Drug Information. Bethesda (Maryland): American Society of Health-System Pharmacists, 2004.
10. Olfson M, Marcus SC, Weissman MM, Jensen PS: National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514-521, 2002.
11. Pastor PN, Reuben CA: Racial and ethnic differences in ADHD and LD in young school-age children: Parental reports in the National Health Interview Survey. Public Health Rep 120:383-92, 2005.
12. Pliszka SR: Psychiatric comorbidities in children with attention deficit hyperactivity disorder: Implications for management. Paediatr Drugs 5:741-750, 2003.
13. Pliszka S: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894-921, 2007.
14. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M: The Texas children's medication algorithm project: Revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642-657, 2006.
15. Radigan M, Lannon P, Rohhan P, Gesten F: Medication patterns for attention-deficit/hyperactivity disorder and comorbid psychiatric conditions in a low-income population. J Child Adolesc Psychopharmacol 15:44-56, 2005.
16. Stevens JJ, Harman S, Kelleher KJ: Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol 15:88-96, 2005.
17. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A: Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 42:24-31, 2008.
18. Zito JM, Safer DJ, DosReis S, Magder LS, Gardner JF, Zarin DA: Psychotherapeutic medication patterns for youths with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 153:1257-1263, 1999.
19. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med 157:17-25, 2003.